Online citations, reference lists, and bibliographies.
← Back to Search

Biomarkers For Malignant Pleural Mesothelioma: A Meta-analysis.

Christina Gillezeau, M. V. van Gerwen, J. Ramos, Bian Liu, R. Flores, E. Taioli
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant Pleural Mesothelioma (MPM) is a rare by aggressive cancer, and early detection is associated with better survival. Mesothelin, fibulin-3, and osteopontin have been suggested as screening biomarkers. The study conducted a meta-analysis of the mean differences of mesothelin, osteopontin, and fibulin-3 in blood and pleural samples. PubMed searches were conducted for studies that measured levels of mesothelin, osteopontin, and fibulin-3 in participants with MPM compared to with malignancy, benign lung disease, or healthy participants. Thirty-two studies with mesothelin levels, 12 studies with osteopontin levels and nine studies with fibulin-3 levels were included in the meta-analysis. Statistically significant mean differences were seen between MPM patients and all other comparison groups for mesothelin blood and pleural levels. Statistically significant differences in blood osteopontin levels were seen between participants with benign lung disease and healthy participants compared to participants with MPM, but not when comparing cancer participants to MPM participants. There were not enough studies that reported osteopontin levels in pleural fluid to complete a meta-analysis. Statistically significant differences were seen in both blood and pleural levels of fibulin-3 in MPM patients compared to all other groups. Based on these results, mesothelin and fibulin-3 levels appear to be significantly lower in all control groups compared to those with MPM, making them good candidates for screening biomarkers. Osteopontin may be a useful biomarker for screening healthy individuals or those with benign lung disease, but would not be useful for screening patients with malignancies.
This paper references
10.1097/MCP.0000000000000167
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma
J. Creaney (2015)
10.1016/j.ctrv.2015.05.001
The established and future biomarkers of malignant pleural mesothelioma.
V. Panou (2015)
10.18632/oncotarget.12707
Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis
Ran Ren (2016)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.21873/ANTICANRES.11460
Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
E. Battolla (2017)
10.1183/09031936.00148211
A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions
C. Hooper (2012)
10.1093/carcin/bgu227
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
F. Baumann (2015)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1007/s00204-010-0580-2
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos
M. Gube (2010)
10.1016/J.CTRV.2007.07.012
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
10.18632/oncotarget.14712
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
Dongxu Pei (2017)
10.1373/clinchem.2008.121913
Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum.
K. Hollevoet (2009)
10.1016/J.EJCDT.2012.10.016
Combined blood and pleural levels of mesothelin and osteopontin for the diagnosis of malignant pleural mesothelioma
Wafaa M. Ashour (2012)
10.3109/07357907.2012.749265
Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
P. Canessa (2013)
10.1016/j.lungcan.2011.02.007
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
J. Creaney (2011)
10.1002/SIM.1186
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
10.21037/jtd.2017.12.17
Biomarkers in the prevention and follow-up of workers exposed to asbestos.
R. Foddis (2018)
10.1177/0004563217741145
Biomarkers in mesothelioma
D. Arnold (2018)
10.21037/jtd.2017.10.132
Serum mesothelin and other biomarkers: what have we learned in the last decade?
A. Cristaudo (2018)
10.1016/j.ijsu.2017.10.034
The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database.
S. Wang (2017)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1016/J.EJCDT.2013.04.005
Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis
F. Amany (2013)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1007/s00408-013-9526-9
Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos
Mehmet Bayram (2013)
10.1016/J.EJCDT.2014.08.001
Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions
A. Elgazzar (2014)
10.1016/J.EJCDT.2013.10.004
Role of fibulin-3 in the diagnosis of malignant mesothelioma
M. Agha (2014)
10.21037/atm.2017.06.60
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
10.21037/jtd.2017.10.88
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
R. Bruno (2018)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.1053/j.semtcvs.2009.06.007
Current status of screening for malignant pleural mesothelioma.
H. Pass (2009)
10.1097/MCP.0b013e32812144bb
Biomarkers for mesothelioma
A. Scherpereel (2007)
10.1002/jcb.20828
Cellular and molecular parameters of mesothelioma
Maria E. Ramos-Nino (2006)
10.1186/1471-2288-5-13
Estimating the mean and variance from the median, range, and the size of a sample
Stela Pudar Hozo (2005)
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
P. Ferro (2013)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1016/j.lungcan.2013.09.016
Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
J. Creaney (2013)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1158/1055-9965.EPI-07-0607
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
M. Amati (2008)
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1097/JTO.0b013e31828f696b
Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer
T. Muley (2013)
10.3892/ETM_00000048
Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.
N. Fujimoto (2010)
10.1016/S1556-0864(15)31535-5
Soluble Mesothelin Related Protein in Mesothelioma
J. Creaney (2006)
10.1055/s-0031-1272874
Update on malignant pleural mesothelioma.
N. Campbell (2011)
10.2217/fon.15.317
Biomarkers and prognostic factors for malignant pleural mesothelioma.
P. Vigneri (2015)
10.1097/JTO.0b013e318187491c
Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer
J. Schneider (2008)
10.1016/j.chest.2016.12.004
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
10.1164/rccm.200811-1729OC
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)
10.5301/JBM.2009.5043
Osteopontin is not a specific marker in malignant pleural mesothelioma.
L. Paleari (2009)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1097/MCP.0b013e328302851d
Malignant mesothelioma 2008
M. Zervos (2008)
10.1016/b978-0-12-394384-2.00006-1
Asbestos-Related Disease
J. R. Portal (2012)
10.1183/09031936.00064413
Mesothelin and osteopontin
I. Pantazopoulos (2013)
10.1093/annhyg/mev060
Mesothelioma among Motor Vehicle Mechanics: An Updated Review and Meta-analysis.
D. Garabrant (2016)
10.1186/s12885-017-3209-5
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
Guntulu Ak (2017)
10.1016/j.jtho.2017.04.002
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
10.1155/2013/874212
Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
J. Creaney (2013)
10.1007/978-3-642-10862-4_10
Early stages of mesothelioma, screening and biomarkers.
S. Klebe (2011)
10.4161/epi.6.8.16074
The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma
H. Nelson (2011)
10.1093/annhyg/mew038
Response to Kay Teschke. Re: Mesothelioma among Motor Vehicle Mechanics: An Updated Review and Meta-analysis.
D. Garabrant (2016)
10.5301/JBM.2011.8614
Biomarkers in Malignant Mesothelioma: Diagnostic and Prognostic Role of Soluble Mesothelin-Related Peptide
N. Dipalma (2011)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1007/s11604-010-0449-6
Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease
S. Kurata (2010)
10.1371/journal.pone.0185850
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
Takehiro Otoshi (2017)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1515/CCLM.2010.066
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels
A. Rai (2010)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1155/2014/413946
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
10.1038/bjc.2017.22
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
D. Arnold (2017)
10.1097/JTO.0b013e31821e1c08
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
A. Cristaudo (2011)
10.3390/cancers10060203
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
C. Ledda (2018)
10.1073/pnas.1821510116
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
R. Hassan (2019)
10.1038/bjc.2015.286
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
M. Kirschner (2015)
10.1517/17530059.2013.786038
Current and future options for the diagnosis of malignant pleural effusion.
F. Rodríguez-Panadero (2013)
10.1155/2017/1725354
Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population
Z. Jiang (2017)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1200/JCO.2018.79.0352
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
S. Pastorino (2018)
10.1097/JTO.0b013e31824c9272
CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions
C. Blanquart (2012)
YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.
M. Corradi (2013)
10.1515/CCLM.2011.242
Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
S. Yamada (2011)
10.1016/j.lungcan.2008.02.012
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
K. Iwahori (2008)
10.1016/j.cca.2014.02.024
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
Z. Hu (2014)
10.21037/atm.2017.04.29
Mesothelioma: recent highlights.
M. Carbone (2017)
10.1177/172460081002500307
Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma
A. Cristaudo (2010)
10.1136/bmj.39343.408449.80
Uncertainty in heterogeneity estimates in meta-analyses
J. Ioannidis (2007)
10.1097/MCP.0b013e32832b98eb
Serum and pleural fluid biomarkers for mesothelioma
J. Creaney (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar